SAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie
|
|
- Domenic Cox
- 5 years ago
- Views:
Transcription
1 Patient Group Direction for the Supply or Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate Vaccine (Infanrix-IPV-HIB) to children aged 3 years 4 months and above as part of their primary vaccination schedule until 3 rd March 2009 attending vaccination clinics in NHS Borders. This document authorises the administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus Type b Conjugate Vaccine (Infanrix-IPV-HIB) by registered nurses to children aged 3 years 4 months and above as part of their primary vaccination schedule until 3 rd March 2009 who meet the criteria for inclusion under the terms of the document. The registered nurse seeking to supply administer combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate vaccine (Infanrix-IPV-HIB) must ensure that all clients have been screened and meet the criteria before supply takes place. The purpose of this Patient Group Direction is to improve access to combined Diphtheria, Tetanus, acellular Pertussis, and inactivated Polio vaccine to ensure adequate population coverage for the vaccine. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie This direction was authorised on 1/11/2007 The direction will be reviewed by 1/11/2009 Clinician Responsible for Training and Review: Dr Tim Patterson
2 Patient Group Direction for Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate vaccine (Infanrix-IPV-HIB) without a Prescription for a Named Individual by registered nurses employed by NHS Borders 1.This Patient Group Direction relates to the following specific Vaccine preparation: Name of Vaccine Legal status Storage Dose Route/method Frequency Total dose number Relevant Warnings Combined Diphtheria. Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate vaccine (Infanrix-IPV-HIB). POM (Prescription only Medicine.) The lyophilised powder and the suspension for injection have to be stored at +2 C to +8 C. The suspension should not be frozen. Discard if it has been frozen. Consult pharmacy if above 8 C 0.5ml Intramuscular injection. Combined DTaP/IPV/Hib vaccine can be given at the same time as other vaccines but at a different injection site, preferably different limbs. If given in the same limb, they should be administered at least 2.5cm apart. Vaccination by deep subcutaneous route should be reserved only for individuals with a bleeding disorder where intramuscular route is contraindicated. For the purpose of this PGD one vaccination only. One It is recommended that the pre-school booster is given three years after completion of primary immunisation, that is at three years and four months of age, or soon after. However, when primary immunisation has been delayed, the pre-school booster may be given at the scheduled preschool immunisation visit, as long as this is at least one year since completion of primary immunisation. Reference: CMO letter SEHD/CMO(2007)(7) Page 5
3 If a child has previously had a severe allergic reaction (which is not anaphylaxis) following immunisation they may be immunised as normal, however, advice should be sought from a GP/Paediatrician as appropriate. If the child has an evolving neurological condition including poorly controlled epilepsy, advice from a Paediatrician should be sought. Infanrix-IPV+Hib immunisation should be delayed until the condition has become stable. Where there is a personal or family history of febrile seizures, there maybe an increased risk of a child experiencing a seizure following immunisation that leads to a fever. In these circumstances advice on the prevention and management of fever should be given before immunisation. There will be very few occasions when deferral is required. The period of deferral should be minimised as it leaves the child unprotected. The circumstances in which deferral may be necessary are detailed below. If a child experienced encephalopathy or encephalitis within 7 days of a previous immunisation, it is unlikely to have been caused by the vaccine, but should still have been investigated. Immunisation should be deferred if no underlying cause was found and the child did not recover completely within 7 days, otherwise immunisation should proceed as recommended. Young children with thrombocytopenia or other bleeding disorder can be given this vaccine, but care should be taken when it is given because of the risk of bleeding. It should be given by deep subcutaneous injection to reduce the risk of bleeding if that is considered appropriate. It is recommended that children with chronic immunodeficiency (such as those with HIV or on longterm immunosuppressive therapy) should be immunised even though they may not mount a full immune response and will only have limited protection. Re-immunisation should be considered when the individual has recovered from the condition or has completed and recovered from the treatment.
4 Side Effects Local reactions (pain, erythema, induration and oedema) within 48 hours after vaccination and persisting for 1-2 days. Fever Anaphylactic reactions are rare but can be fatal Guillain-Barré Syndrome has been reported as a very rare, late reaction after vaccination with tetanus toxoid containing vaccine. Advice to Parents Follow up Arrangements For full details of side effects, the product literature should always be consulted. Temperature control. Management of local reactions Issue manufacturer s patient information leaflet if available. Observe for signs of anaphylaxis and treat as per current guidelines. Parent/guardian asked to seek medical advice for significant side effects or if concerned. Parent/guardian to inform GP/Nurse of any adverse reactions or if concerned. This is a black triangle medicine. All suspected reactions should be reported directly to CSM Scotland ( ) through the yellow card scheme and recorded in the patient s medical records. Yellow cards are available at the back of the BNF. GP appointment/duty GP depending on urgency. 2. Clinical condition Clinical Condition to be treated A pre-school booster vaccination, to be used during the Hib Catch-up Programme, against Diphtheria, tetanus, Pertussis, Poliomyelitis and Hib in children aged from 3 years 4 months old to under 6 years of age*. Children in the eligible group for the Hib Catch Up
5 Programme are those born between 4 th April 2003 and 3 rd September Note* This recommendation to use Infanrix-IPV+Hib in children over 36 months of age is off-licence, but is in line with the recommendation of JCVI as contained in the CMO letter. Signed consent for immunisation is required in all cases. Criteria for inclusion Children in the eligible group aged from 3 years 4 months old to under 6 years of age where: Parent/guardian consent has been given to receive the vaccine. A booster of Diphtheria, tetanus, Pertussis, poliomyelitis and Hib is indicated. A primary course of three doses of diphtheria, Tetanus, Pertussis, Poliomyelitis and Hib has been given. The primary course should ideally have been completed at least 3 years previously (but see first bullet point in Cautions/further information). Criteria for exclusion Any individual who has had a true anaphylactic reaction to a previous dose of Diphtheria, Tetanus, Pertussis, live/inactivated Poliomyelitis or Hib. A true anaphylactic reaction to, neomycin, polymyxin or polysorbate 80 (which may be present in trace amounts) or to any excipient (additive) of the vaccine. (Consult SPC or manufacturer s package leaflet.). No valid consent. Where there is less than 1 year since the completion of primary immunisation. Child in the eligible group, who has already received a pre-school booster with a vaccine that did not have a Hib component. (i.e. It was either dtap/ipv (Repevax) or DTaP/IPV (Infanrix IPV). Go to PGD for Hib/Men C (Menitorix). If a child is ill with a fever immunisation should be postponed until the child has recovered. Action if excluded Febrile or current viral infection - make another appointment.
6 A child in the eligible group, who has already received a pre-school booster with a vaccine that did not have a Hib component, should be offered a further vaccination with Hib/Men C. Where there is a personal or family history of febrile seizures there maybe an increased risk of a child experiencing a seizure following immunisation, which leads to a fever. In these circumstances advice should be given by the nurse on the prevention and management of fever before immunisation. Action if declines Interactions with other medicaments and other forms of interaction All others -seek advice from a Registered Medical Practitioner (General Practitioner, Paediatrician or Consultant in Public Health Medicine as appropriate). The risk to the individual of not being immunised must be taken into account. Ensure patient/parent/guardian is aware of risk of disease. Record in medical records. If further advice is required, discuss with a Registered Medical Practitioner (General Practitioner, Paediatrician or Consultant in Public Health Medicine as appropriate). INFANRIX -IPV+Hib should not be mixed with other vaccines or medicinal products in the same syringe. 3. Records- GPASS or GP Patient Record 1. The following records should be kept (either paper or computer based) The GP practice, clinic, hospital, and ward or department.
7 The patient name and CHI number. The medicine name, dose, route, time of dose(s), and where appropriate, start date, number of doses and or period of time, for which the medicine is to be supplied or administered. Drug batch number and expiry. The signature and printed name of the approved healthcare professional who supplied or administered the medicine. The patient group direction title and/or number. Whether patient met the inclusion criteria and whether the exclusion criteria were assessed. Quantity supplied / received and current stock balance (Appendix 4). 2. Preparation, audit trail, data collection and reconciliation- Stock balances should be reconcilable with Receipts, Administration, Records and Disposals on a patient by patient basis. 3. Storage- The lyophilised powder and the suspension for injection have to be stored at +2 C to +8 C. The suspension should not be frozen. Discard if it has been frozen. 4. Anaphylaxis Emergency Treatment (if appropriate for individual vaccination PGDs) When giving any vaccination the following should be available: Access to the patients notes. Epinephrine (Adrenaline) 1 in 1000 for i.m. use in emergency (NB: check expiry dates regularly). Syringes and needles of suitable size and capacity for dose. Epinephrine (Adrenaline) 1 in1000 For intramuscular injection (1mg/ml) Age Volume of epinephrine (adrenaline) 1 in 1000 (1mg/ml) Under 6 months 0.05ml 6months to 6 years 0.12ml 6 12 years 0.25ml Adults and adolescents 0.5ml These doses may be repeated if necessary at 5 minute intervals according to blood pressure, pulse and respiratory function. Special cautions: see BNF Epinephrine/ Adrenaline BNF (54 th edition) section page 168 and 169
8 5. Professional Responsibility All Health Professionals will ensure he/she has the relevant training and is competent in all aspects of medication, including contraindications and the recognition and treatment of adverse effects. He/she will attend training updates as appropriate. For those involved in immunisation, regular anaphylaxis updates are mandatory. Nurses will have due regard for the NMC code of Professional Conduct: standards for conduct, performance and ethics (0704) and NMC Guidelines for administration of medicines (0104) Sources of Evidence used for the PGD. Immunisation against Infectious Disease The Green Book See the latest Chapters (Currently December 2006) available at CMO letter SEHD/CMO(2007)(7) Haemophilus Influenzae Type B (HIB) vaccine for young children catch-up programme. Draft Example PGD for Infanrix-IPV+Hib from the NHS Immunisation website available at British National Formulary (BNF) current edition (54 th ).
9
SAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationThis document expires on Patient Group Direction No. VI 5
Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) Or Adsorbed DIPHTHERIA/TETANUS/acellular
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of HAEMOPHILUS INFLUENZAE TYPE B AND MENINGOCOCCAL C CONJUGATE VACCINE (HIB-MenC) MENITORIX Vaccine By Registered Nurse/Midwife/Health Visitor
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Central Midlands Area may only be used by members of the healthcare professions named on the title page, and only if each professional has
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationPatient Group Direction No. VI 17. Kathy Wakefield/Lisa Murray. General Practices & TRFT. Relevant Clinical Lead
T i:1 Patient Group Direction (PGD) for The Administration of Meningococcal Group C Conjugate Vaccine (Meningitec /NeisVac-C /Menjugate Kit ) by Registered Nurses employed or commissioned by NHS Rotherham
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationPatient Group Direction (PGD) Number (minor amendment June 2014):
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationClinical Condition Indication:
Patient Group Direction ( for Health Care GG&C PGD ref no: 2018/1611 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition
More informationCLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )
Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN
More informationDirection Number: - NECSAT 2014/014
Patient Group Direction (PGD) for the Administration of COMBINED DIPHTHERIA, TETANUS, ACELLULAR PERTUSSIS AND INACTIVATED POLIOMYELITIS VACCINE (Repevax / Infanrix IPV ) by Registered Professionals to
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationby registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationGG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationPGD No Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil - September 2012
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationabcdefghijklm abcde abc a `ÜáÉÑ=jÉÇáÅ~ä=lÑÑáÅÉê=aáêÉÅíçê~íÉ= HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINE FOR YOUNG CHILDREN CATCH-UP PROGRAMME
abcdefghijklm `ÜáÉÑ=jÉÇáÅ~ä=lÑÑáÅÉê=aáêÉÅíçê~íÉ= HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINE FOR YOUNG CHILDREN CATCH-UP PROGRAMME This letter explains a Haemophilus influenzae type b (Hib) vaccination
More informationVaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives. August 2014
Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives August 2014 Quality Education for a Healthier Scotland 1 Key Message There is a lot
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) By Registered Nurse/Midwife/Health Visitor
More informationCONJUGATE MENINGOCOCCAL (ACWY) VACCINE
Cumbria & Lancashire Vaccine PGD Group ADVISORY INFORMATION FOR USE WITH PATIENT SPECIFIC DIRECTION OR INDIVIDUAL PRESCRIPTION SIGNED BY GP OR NON-MEDICAL PRESCRIBER. CONJUGATE MENINGOCOCCAL (ACWY) VACCINE
More informationDirection Number: - NECSAT 2014/010
Patient Group Direction (PGD) for the Administration of COMBINED DIPHTHERIA, TETANUS, ACELLULAR PERTUSSIS and INACTIVATED POLIO AND HIB VACCINE (DTaP/IPV/Hib PEDIACEL and Infanrix IPV + Hib) by Registered
More informationGG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation
More informationAdministration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.
Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors. Special notes PPD is an unlicensed medicine and therefore
More informationClinical Condition Indication:
GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationUNSCHEDULED VACCINATION OF CHILDREN AND YOUNG PEOPLE WHO HAVE OUTSTANDING ROUTINE IMMUNISATIONS. Service Specification
UNSCHEDULED VACCINATION OF CHILDREN AND YOUNG PEOPLE WHO HAVE OUTSTANDING ROUTINE IMMUNISATIONS Service Specification National Enhanced Service Specification For The Unscheduled Vaccination Of Children
More informationPatient Group Direction for Measles, Mumps & Rubella Vaccine. PGD Version No.: 7/2013.
Document Title: Patient Group Direction for Measles, Mumps & Rubella Vaccine Area Team Doc Ref.: PGD Version No.: 7/2013 Doc Ref.: http://www.england.nhs.uk/mids-east/ss-at/immunisations/ Author: Owner:
More informationDirection Number: - NECSAT 2014/007
Patient Group Direction (PGD) for the Administration of COMBINED LOW DOSE DIPTHERIA, TETANUS AND INACTIVATED POLIO VACCINE (Td/IPV Revaxis ) by Registered Professionals to Individuals Accessing NHS Services
More informationClinical Condition Indication:
GG&C PGD ref no: 2016/1366 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationChange history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015.
Patient Group Direction for Conjugate Meningococcal ACWY vaccine Version: MEN ACWY CONJUGATE 2015.1 Start 1 st August 2015 Expiry 31 st July 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING
More informationpatient group direction
REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic
More informationVaccination against pertussis (whooping cough) an update for registered healthcare practitioners Questions and Answers
Vaccination against pertussis (whooping cough) an update for registered healthcare practitioners Questions and Answers April 2016 Health Protection Scotland is a division of NHS National Services Scotland.
More informationSAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009
Patient Group Direction for the Supply and Administration of Flumazenil 100microgram Injection To Patients requiring reversal of oversedation due to midazolam in association withendoscopy attending Endoscopy
More informationHEPATITIS A + TYPHOID VACCINE
GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation
More informationPatient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015
Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B 2014.1 Start 1 st January 2014 Expiry 31 st December 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationTEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN
TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN Richard Smithson Neil Irvine Maureen McCartney Consultant Health Protection October 2012 Pertussis/whooping cough The disease Whooping Cough
More informationPatient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018
Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL
More informationAdministration of shingles (herpes zoster) vaccine (live) Zostavax. Version 7.0 updated for programme from September 2017 to August 2018
Patient Group Direction template Administration of shingles (herpes zoster) vaccine (live) Zostavax Version 7.0 updated for programme from September 2017 to August 2018 This specimen Patient Group Direction
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationGG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Individuals requiring active immunisation
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationAdministration of Hepatitis A and B Vaccine
PRACTICE: Ref No: PGD/ONEL/2011/006 Valid from December 2011 Valid to December 2013 Supersedes PGD: Any previous PGD used to administer Twinrix Adult and Paediatric vaccine Professional groups covered
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of COMBINED HEPATITIS A AND HEPATITIS B VACCINE TWINRIX PAEDIATRIC For Children aged 1 year to under 16 years TWINRIX ADULT For Adults and Adolescents
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:
More informationPatient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015
Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS-2013. 1 (Rotarix ) Start 1 st July 2013 Expiry 30 th June 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationBASIC IMMUNISATION FOR NEW IMMUNISERS. Alison Johnson Immunisation Facilitator.
BASIC IMMUNISATION FOR NEW IMMUNISERS Alison Johnson Immunisation Facilitator. Contents. Why vaccinate? Basic Immunology UK immunisation programme/selective Policies and guidelines. Cold chain Consent
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPatient Group Direction for the Administration of Haemophilus Influenzae Type b and Meningococcal C conjugated vaccine (Hib/MenC - Menitorex )
Patient Group Direction for the Administration of Haemophilus Influenzae Type b and Meningococcal C conjugated vaccine (Hib/MenC - Menitorex ) This PGD must be read in conjunction with the core PGD (Reference:
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationGG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.
More informationPatient Group Direction for HEPATITIS A AND TYPHOID VACCINE. Version No.: 4/2014. Hitesh Patel Pharmaceutical Adviser, NHS Telford & Wrekin CCG
Document Title: Patient Group Direction for HEPATITIS A AND TYPHOID VACCINE PCT Doc Ref.: Local Doc Ref.: PGD Version No.: 4/2014 Author/Owner: File Reference: Document Overseeing Group: Hitesh Patel Pharmaceutical
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationChildhood Immunisations Template Guide 2016
Childhood Immunisations Template Guide 2016 1 Template Control Page Childhood Immunisations Template Guide Title Childhood Immunisations Author CEG Version 9 Description Supports the schedule of Childhood
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationPatient Group Direction
This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final
More informationConsultation Group: See relevant page in the PGD. Review Date: April Expiry Date: April 2020
Patient Group Direction For The Administration Of Low Dose Diphtheria, Tetanus And Inactivated Poliomyelitis Vaccine dt/ipv (Revaxis ) By Nurses, Midwives, Health Visitors And Pharmacists Working Within
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationVaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives
Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for midwives August 2014 Quality Education for a Healthier Scotland 1 Background As you will be
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV) Section 7: Biological Product Information Standard #: 07.212 Created by: Province-wide Immunization Program Standards
More informationGG&C PGD ref no: 2016/1309 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1309 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Prevention of shingles (herpes
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for registered healthcare practitioners about the inclusion of hepatitis B vaccine in the routine infant immunisation programme July 2017
More informationPertussis immunisation for pregnant women
Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis. Before the introduction
More informationVaccination against pertussis(whooping cough)
Vaccination against pertussis(whooping cough) Vaccination now recommended from 16 weeks of pregnancy An update for registered healthcare practitioners February 2018 additions and/or revisions of any kind
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019
Patient Group Direction for Varicella vaccine Version: Varicella 2016.1 Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for healthcare practitioners about the inclusion of hepatitis B vaccine in the routine infant immunisation programme About Public Health
More informationPGD Version No.: 3/
Document Title: Patient Group Direction for Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Prevenar 13 ( ) Area Team Doc Ref.: PGD Version No.: 3/2014 NHS Doc Ref.: Author: Owner:
More informationVersion Number: 02. Patient Group Direction drawn up by: Jayne Bruce - Deputy Director of Nursing Standards and Safety Sussex
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF INFLUENZA VACCINE BY REGISTERED NURSES (PEER VACCINATORS) TO STAFF WORKING FOR SUSSEX PARTNERSHIP NHS FOUNDATION TRUST Version Number: 02 Patient
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX Haemophilus type b conjugated vaccine IP 1. NAME OF THE MEDICINAL PRODUCT Haemophilus type b conjugated vaccine
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for healthcare practitioners about the inclusion of hepatitis B vaccine in the routine infant immunisation programme About Public Health
More informationDirection Number: - NECSAT 2014/012
Patient Group Direction (PGD) for the Administration of SHINGLES (Herpes Zoster) VACCINE by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and Cumbria,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. INFANRIX-IPV+Hib powder and suspension for suspension for injection
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT INFANRIX-IPV+Hib powder and suspension for suspension for injection Diphtheria (D), tetanus (T), pertussis (acellular component) (Pa),
More informationTable of Contents. 1.0 INFANRIX hexa VACCINE...3
Table of Contents 1.0 INFANRIX hexa VACCINE...3 1.1 What is INFANRIX hexa vaccine?...3 1.2 When will INFANRIX hexa be introduced?...3 1.3 What is the difference between INFANRIX hexa and Pediacel?...3
More informationDirection Number: - NECSAT 2015/016
Patient Group Direction (PGD) for the Administration of SHINGLES (Herpes Zoster) VACCINE by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees, Cumbria, Northumberland
More informationThis Patient Group Direction has been developed/reviewed in accordance with NICE guidance by:- Position of Signatory Name Signed Date
Patient Group Direction Administration of Hepatitis B Vaccine By Registered Nurses employed by GP Practices within Stafford & Surrounds Clinical Commissioning Group This Patient Group Direction has been
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Infanrix-IPV+Hib 1 SPC Vial + Vial 1. NAME OF THE MEDICINAL PRODUCT INFANRIX-IPV+Hib powder and suspension for suspension for injection Diphtheria, tetanus, pertussis
More informationPATIENT GROUP DIRECTION (PGD)
PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX 1. QUALITATIVE AND QUANTITATIVE COMPOSITION contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and 69 kilodalton
More informationChildhood Immunisations Template Guide 2017
Childhood Immunisations Template Guide 2017 1 Template Control Page Childhood Immunisations Template Guide Title Childhood Immunisations Author CEG Description Supports the schedule of Childhood Immunisations
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands) Patient Group Direction for the administration of Bexsero suspension for injection (Meningococcal
More informationIMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe
IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe Read all of this leaflet carefully before you are vaccinated or before you have your child vaccinated. Keep
More informationBOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine
BOOSTRIX Combined diphtheria, tetanus, acellular pertussis vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus toxoid 1 Bordetella pertussis antigens
More informationThe hexavalent DTaP/IPV/Hib/ HepB combination vaccine
The hexavalent DTaP/IPV/Hib/ HepB combination vaccine Greenwich Practice Nurse Forum Oct 17 th 2017 Introduction of a hexavalent infant vaccine From autumn 2017, all babies born on or after 1 August 2017
More informationPatient Group Direction For The Pre-Exposure Prophylactic Administration Of Rabies Vaccine By Nurses And Pharmacists Working Within NHS Grampian
NHS Grampian Patient Group Direction For The Pre-Exposure Prophylactic Administration Of Rabies Vaccine By Nurses And Pharmacists Working Within NHS Grampian Lead Author: Consultation Group: Approver:
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF COMBINED HEPATITIS A&B VACCINE
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF COMBINED HEPATITIS A&B VACCINE Valid from: June 2016 Review date: May 2018 Expiry date: June 2018 Developed by Name Job Title Signature Date Senior
More information